Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Coenzyme rare to bacteria critical to Mycobacterium tuberculosis survival

Coenzyme F420, a small molecule that helps certain enzymes transfer electrons, is found in microorganisms known as methane-producing archaea, some of which thrive in extreme environments.

It also helps the bacterium that causes tuberculosis (TB) to survive the defenses of the human immune system. Scientists have now discovered at least one way F420 helps to arm the pathogen.

The research will appear in the early online issue of the Proceedings of the National Academy of Science (PNAS) during the week of March 23, 2009, in the article, "Conversion of NO2 to NO by Reduced Coenzyme F420 Protects Mycobacteria from Nitrosative Damage," by Endang Purwantini and Biswarup Mukhopadhyay, both with the Virginia Bioinformatics Institute (VBI) at Virginia Tech.

Mukhopadhyay's lab specializes in the study of the anaerobic archaea, especially those that produce methane, and has a program on enzymes that utilize coenzyme F420.

Coenzyme F420 is rare in bacteria. Only the Actinobacteria, a group of aerobic microorganisms, contain F420. They include the mycobacteria, which generally live in the soil, except for Mycobacterium tuberculosis (Mtb), which causes TB.

In 1996, Purwantini as a graduate student in the laboratory of Lacy Daniels, then at the University of Iowa, discovered an enzyme that reduces F420 by adding two electrons and one proton to it, producing F420H2. This discovery raised the question, "What is the use of F420H2 in a mycobacterial cell?"

In 2000, the PathoGenesis Corporation developed a new anti-TB drug called PA-824 that is converted into an active form within the Mtb cells. Further research by others showed that this conversion requires F420H2. "But that would hardly seem to be why the bacterium makes F420H2," said Mukhopadhyay, assistant professor with VBI and adjunct assistant professor in the Departments of Biochemistry and Biological Sciences. "The organism must have a use for F420H2 that is advantageous to itself."

To find clues to how mycobacteria use F420H2, Purwantini, by this time a senior scientist at VBI, considered the battle between the human immune system and Mtb. Immune cells called macrophages engulf Mtb cells and bombard the pathogen with oxidizing compounds, such as hydrogen peroxide, superoxide, and nitric oxide (NO). In addition, macrophages convert NO into more deadly nitrogen dioxide (NO2). Mtb can withstand these attacks. Based on earlier research by others, there were indications that F420 is in some way responsible for this resilience of the Mtb.

Purwantini focused on the defense of Mtb against NO2 and found that F420H2 reacts with NO2, converting it into much less harmful NO. Purwantini and Mukhopadhyay theorized the following possibility: As a macrophage generates NO and then converts it to NO2, Mtb responds by converting NO2 back to the less toxic NO by using F420H2, buying time until the macrophage dies. Mtb then becomes dormant within the dead macrophage, lurking at the heart of the immune system until the system has a weak moment – perhaps as a result of HIV or poor nutrition.

To support this hypothesis, they conducted tests with Mycobacterium smegmatis, a nonpathogenic cousin of Mtb. Wildtype M. smegmatis survived almost as well in the presence of NO2 as it did in water. But when the researchers knocked out one of the genes required for the synthesis of F420, the bacterium became very sensitive to NO2. They got the same result by knocking out the gene that coded for the enzyme that produces F420H2. When those genes were restored, M. smegmatis regained its resistance to NO2.

Are there other examples for such a defense system? The team found an answer to that question in the literature. Research in early 1990's showed that gamma-tocopherol, a type of vitamin E that is found in certain food materials, converts NO2 to NO and thereby prevents transformation of normal human cells to malignant tumor cells by NO2.

Purwantini and Mukhopadhyay added that, "We know the biochemistry of F420 really well based on the work on methane-producing archaea by us and others and we were able to apply that knowledge to our work on the mycobacetria. It shows how basic science information from different fields can contribute to each other."

What's next? In the immediate future, Purwantini and Mukhopadhyay want to determine the chemical mechanism of the reaction. In the long-term, they want to develop a way to intervene in F420H2 production in the Mtb cell, which will make the organism more prone to being killed by the human immune system. They also speculate that the reaction that they have found may act as a sensor. Mtb could use this reaction to gauge whether a host is capable of making NO2 and therefore immuno competent. In the absence of this reaction, Mtb could wake up from dormancy and cause active TB. This idea has a parallel in methanogenic archaea where F420 has been proposed as a probe for assessing hydrogen availability.

Lacy Daniels, now professor of pharmaceutical sciences with the Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, said of Purwantini and Mukhopadhyay's continuation of his early work, "This discovery provides the first solid evidence that F420 is truly important for the ability of Mtb to cause disease. It will clearly stimulate efforts to study the role of F420 in animal disease models, and to study inhibitors of F420 metabolism as potential anti-TB drugs."

Robert White, associate professor of biochemistry at Virginia Tech and an expert on biosynthesis, structure, function, and genetics of the coenzymes, said of the research, "This work establishes a new function for a well studied coenzyme that is known to have only a limited distribution in microorganisms. It represents a fine example of basic scientific research providing leads for new drug targets."

Mukhopadhyay is corresponding author. Reach him at 540-231-8015 or Learn more about his work at:

AFTER THIS ARTICLE PUBLISHES, it will be available at

Susan Trulove | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>